🇺🇸 FDA
Patent

US 12297509

Biomarkers for predicting tumor response to and toxicity of immunotherapy

granted A61KA61K2039/505A61K39/00

Quick answer

US patent 12297509 (Biomarkers for predicting tumor response to and toxicity of immunotherapy) held by MIRA DX, INC. expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MIRA DX, INC.
Grant date
Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K39/00, A61P, A61P35/00